Hey Ken, as Tobin Smith keeps saying, I'm ready for some of that life changing wealth. The market is moving NEOM up anticipating good news to come. The Virgin settlement and a major licensing deal appear to be close. It's hard to model Neom, but I'm using SIRI for now and it doesn't have anywhere near the potential of NEOM. TW

Hey Ken, welcome aboard. Neom has a lot of potential. TW

You've got my permission. The Marx/Smith remark was amazing. We need to start P1 and get some human data to slow those hedgies down. BTK got hit hard today. The DNA effect must be wearing off. If the BTK rolls over, all the small bios get hit. I've noticed the best time to buy is in the afternoon when the hedgies come out of hiding and pound us. Seems like they wait for the buyers to get done in the morning. I agree that the IND viral may come quicker than we think. But, of course, we are still on Tustin time. TW

Kokonot guy, as long as we are trying to model the potential price of neom, it may be productive to take a look at SIRI. Our float is about 1/3 of theirs and I think NEOM has more potential. JMHO

Katie, understood and I agree for the most part. It just seems lately that everyone out there is saying they got a cancer drug that shows promise. I'm just trying to avoid the "oh, another one" remark where we get lumped together with the rest. If we ever get P1 started, if it appears to be safe and if PPHM can get their virologists to develop a protocol, I would like to see them go off shore for some clinical work. They are way underfunded and they proceed like they have all the time in the world with no semblance of urgency. TW

Katie, have to disagree with you on the viral. It's cheaper and quicker to develop. Few companies have anything like Tarvacin. We have no money and no deals. Viral should be developed with at least the same timeline as the cancer.

CJ, woops. Seems I'm always a day late. TW

Looking forward to Friday and Phil's trip to New York. Hope he has some answers to the panelist's questions that are meaningful. The audio tape should be very interesting. If he wants separation distance from the other emerging bios out there, he should hit the viral real hard along with pancreatic cancer. Edelman needs to coach. TW

GILD has drugs treating HIV and Hepatitus B and C. Their stock is up between 700 and 800% in the last 5 years despite the market crash. Hopefully we are seeing the future for 3G4 viral. If it works, the market will not effect our long term stock price. TW

Does anyone know if we have any relationship with GILD. They have a lot to loose if 3G4 works as anticipated. TW

This guy's track record would indicate that it makes a lot of sense for PPHM to push viral at least as strongly as cancer for 3G4. Not much out there to treat viral illnesses so the need for 3G4 is immediate. TW

Terry, the question is whether Tobin can dance. We know he likes a good glass of wine. Maybe this is SK's way of getting even with the hedgies. No doubt, Tobin is one of the biggest pumpers out there. Let's get some human data so Edelman can do its job. TW

Terry, Tobin has a strong following in the momentum crowd. He has just started a NEW biotech letter that is very expensive. PPHM would be a very strong candidate for this service. This could be the start of the sellside support we have been lacking. It would be nice to see PPHM mentioned a few times on FOX. TW

Ken, I use John Murphy for market overview and he is bearish looking for 1050 on the S&P. He, like many others, is not infallible and we are oversold. However, I have used his methods for years and I am comfortable with them. Without news, I expect us to trade with the market. My biggest interest right now is researching the toxicity issue reading back over some of the more technical posts, Thorpe's patents and Oct. lecture. Maybe Katie, CJ or Terry have some thoughts on what P1 is likely to show. If safe in humans, I do not think our share price will look back regardless of the market. PPHM will go its own way. TW

Looks like we are about to enter an info vacuum. Apparently we are not going to be doing a presentation at ASCO and we may not get a PR on the start of P1. Makes us vulnerable to the hedgies. If Tarvacin is truly not toxic to humans, I say we have a big winner. That's the immediate issue and Thorpe statements to date re primates are reassuring. Once the drip starts, the hedgies will find their lives to be much more difficult. Right now it's all about toxicity and waiting. TW

Katie, looks like you got a little of SK's attention. I view the 30 day remark as a response to the inquiries about P1 enrollment. TW

Note that the PR says that PPHM "expects" to begin enrollment in the next 30 days. A forward looking statement. ASCO is 5/13 to 5/17, roughly 30 days away. Wouldn't it be nice if that got P1 going before ASCO. Talk about a PR opportunity. TW

Looks like we finally enroll in the next 30 days. Tustin time. TW

Katie, as usual, I may not have been as clear as I should have been. The disclaimer language is not specific to VTA but applies to forward looking statements by the company of all types and I expect we will see it more frequently in the future as they try to lawyer proof their PR's, regardless of the potential product. I believe that we just happen to notice it first in the context of VTA. I am sympathetic to the frustration we all feel when the company does not hold CC's but I can only conclude they must be concerned that SK might make a mistake. I hope it is not because he has better things to do. Of course, what does that say. Paging Dr. Thorpe, TW

They are in the business of developing biotech products. They are walking a fine line between what they are doing now and what they intend to do in the future. If they do not try and protect themselves from opportunistic lawyers, their underfunded company may not have the money for their future plans. Ain't life great. TW

Katie, it doesn't imply, it says PPHM is not obligated to update forward looking statements in the PR and disclaims any obligation to do so. PPHM does not want to be in the business of giving investment advise that people rely on when it comes to their future plans. Example, they say that VEA may have great potential for improving the efficacy of other drugs,but they may run out of money to do the work to bring VEA to market. They could shelve the plan and not tell you. They don't want you to place undue reliance on their intent to do so when their plans may change for whatever reasons. They may say that they plan on developing VEA, but it may never happen. You invest at your own risk when it comes to that type of statement. I think it is fair game to ask why they plan on a P1 for 3G4 viral, but they may not say much beyond Thorpe's published work. 3G4 human testing for viral could never happen. Hope it does. Thats the risk I take in buying PPHM. TW

Disclaimer is lawyer junk to protect against lawsuits. They still have to tell us about material events. The chart looks really ugly for the next few weeks. Hedgies own us short term. The one and only reason I own this stock is for the viral indications. Hopefully we bottom before ASCO., TW

Katie, having rethought the PR on the beginning of P1, it is no doubt a material event. Accordingly, I expect a PR on it. When????? Who knows. Trying to be patient, TW

Katie, great post. Thanks, TW

Katie, I e-mailed FH a direct question on whether PPHM would PR the start of P1 Tarvacin. Got no answer and that is a first. Must have been a tough question. TW

Terry, nice to see that Melton is finally paying up. j/k TW

Katie, I agree with the idea that PPHM may release a sentence or two that they have started the P1 about the time of AACR (April 16 to 20). I don't know that they will do a separate PR on the subject. I expect it (the reference) to be included in the materials that pertain to the AACR. They are foolish if they don't get it going before ASCO. IMHO TW

The words "in the near term" are deleted. Read the last sentence above the section on viral APT. TW

Katie, the APT section on the PPHM website says that the P1 trial "is" being initiated. It is going to happen. TW

Hey Braingraft, saw your 2C3 post over on RB. Really doing your homework. Here we are 2 years post the May 20,2003 PR and little has been done with 2C3. Apparently, PPHM believes that Tarvacin is a much better drug. After reading the 10-Q, I hope SK did not list in order their priorities for future R&D. I hate to see Cotara becoming important again. It is clear to me that 3G4 viral should be getting the most attention after Tarvacin cancer. That way we can leverage the P1 results. Obviously, they have to follow through on the Cotara/NCI project, but resourses are limited. Seems like a DNA competitor should be interested in a license for 2C3. TW

Q3 is next week. It's a good time for SK to announce that they are beginng P1 Tarvacin and the manufacturing by Avid of the Halozyme products. Some call it the SK version of a CC. TW

Yes, but gallery page works. Cup and handle pattern coming up. PPHM chart is strong. TW

Ken, nice call on the Monday open. I think we are going to run for a while. The story is just beginning to get out and no one, except us, is talking about my favorite topic, VIRUSES. TW

If the rumor of us going to Africa this summer is true, it will confirm a more aggressive attitude by PPHM in moving their technology forward. When summer arrives, PPHM will have 2 to 3 months of P1 data with Tarvacin to look at. If they go in late summer, P1 will be almost done. 3G4 viral in Africa with Dr. Marx at the helm will fundamentally change PPHM's future. I just hope they monitor the before and after viral presence in the P1 patients blood samples to see if there is a noticeable change. I e-mailed SK with Keeptrying's idea. TW

Ken, what's your take on the TA. Charts seems to be firming up (heard that before, right) and looks like we FINALLY may be able to sustain a rally and break above 1.40. I'm sticking with my prediction we will be substantially higher by the end of May. I'm also looking for a big fall but that has more to do with what I hope is progress on viral 3G4. TW

We must be getting real close to some Tarvacin news. Warmed over Cotara news does not explain this type of rise in pps. TW

Katie, very enjoyable read. Paragrah 911 (interesting coincidence) is a big one for me since Dr. Thorpe is saying the invention is suitable to treat viruses that may be used in bio-terrorism. Also nice to see hepatitus C as one of the viruses it may treat. We are going to get noticed and we shouldn't have to wait too long. TW

Katie, don't forget to mention that Drs. Marx and Smith have decided to participate in the development of 3G4. I'm sure they are aware of their reputations. TW

Katie, if you can put them on notice of 3G4, please do. Right now I can't tell if Edelman has started the process of getting the word out on PPHM. Enough events are starting to occur that they should be getting to work. P1 and the April viral data should be promoted. In order for us to move up, we will need to eventually attract sellside support. TW

Revenue and execution will build some credibility. A lot of people don't think much of poster presentations but it is a step in the right direction. Edelman needs to get to work. By the time we are asked to speak on the main stage at ASCO our share price will be a lot higher. It's only a matter of time before Dr. Thorpe gets invited to the big show. TW